Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 3 of Bionano Symposium 2026, entitled OGM Making its Mark in Constitutional Genetic Disorders. Presentations highlighted how ...

As shelf-stable microarray patch (MAP) platforms move through development and clinical work, a ‘packaging first’ mentality is ...

The panel ensures compatibility with our previous autosomal Family Finder tests plus all the autosomal transfers we ...

Multiplexing Breakthroughs, Automation, and Bioinformatics Convergence Position Protein Microarrays as a Strategic Imperative for Precision Medicine LeadersDelray Beach, FL, Feb. 24, 2026 (GLOBE ...

Clinicians should prioritize genetic testing for young children who show signs of intellectual disability (ID) or developmental delays, according to a new report from the American Academy of ...

The Genomics Core offers a variety of microarray analysis options for DNA and epigenetic studies. The Illumina BeadArray technology combined with the Illumina iScan Array Scanner allows for analysis ...

Pharmacogenomic (PGx) testing is a growing area of personalized medicine with demonstrated clinical utility in improving patient outcomes in oncology. PGx testing of pharmacogenes affecting drug ...

As per precedence Research, the global DNA microarray market size is projected to grow approximately USD 6.13 billion by 2034 from valued at USD 2.28 billion in 2023. It is expanding at a CAGR of 9.4% ...

Each month, The Clinical Advisor makes one new clinical feature available ahead of print. Don’t forget to take the poll. The results will be published in the next month’s issue. Healthcare providers ...

A single genetic test could potentially replace the current two-step approach to diagnosing rare developmental disorders in children. This shift could enable earlier diagnoses for families and save ...